Overview

Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder

Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Stanford University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Suvorexant